Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Drinkaware's Response To Public Health Commission Report About Health Messages, UK
In response to a report by the Public Health Commission which says health messages need greater clarity and consistency to help people make the right choices, Chris Sorek, Chief Executive of Drinkaware, says:
generic viagra online
San Francisco Chronicle Profiles U.S. Global AIDS Coordinator
"Dr. Eric Goosby wasted no time starting his new job as the U.S. global AIDS coordinator. He flew from the Bay Area to Geneva hours after his confirmation by the Senate and was sworn in when he landed ò€¦ The ambassador is approaching his post with the urgency of a clinician who has spent more than 25 years fighting the disease," the San Francisco Chronicle writes.
News of the day
Higher Adherence To CPAP Therapy In Men Who Work With Their Female Partners
Men who work with their female partners while receiving continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) are more likely to adhere to their treatment, according to a research abstract presented on Monday at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
Diagnostics

Small Clinical Trial Examines Drug's Ability To Reduce HIV In Body

In the first human trial of GlaxoSmithKline"s (GSK) experimental HIV drug S/GSK1349572, the drug was able to reduce HIV to undetectable levels in 70 percent of the 35 patients taking the treatment for 10 days, according to findings presented at the International AIDS Society"s conference in Cape Town, South Africa, Bloomberg reports. The drug decreased the virus in the body "without the signs of resistance linked to treatments from" Merck"s Isentress and Gilead Sciences" Elvitegravir, according to Bloomberg. GSK will begin a larger trial of the drug this month, Sherene Min, the director of clinical pharmacology discovery medicine for GSK, said. Michael Saag, director of the Center for AIDS Research at the University of Alabama, who is not affiliated with the study, said the scale of viral reduction was "spectacular," adding, "In 10 days to go to undetectable is pretty strong. This thing"s working" (Bennett, 7/21). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009